Whalesbook
The Innovation Imperative
Pharma industry stalwarts made it unequivocally clear: the era of relying solely on generics is over. At a panel discussion during the launch of "Made in India: The Story of Desh Bandhu Gupta, Lupin and Indian Pharma," seasoned leaders emphasized that sustained growth now hinges on genuine innovation. This sentiment was echoed by Dilip Shanghvi of Sun Pharma, who highlighted his company's own evolution from a single-drug focus to a powerhouse in both generics and novel therapies, stressing the commitment of significant resources to R&D with uncertain outcomes.
Competitive Pressures Mount
The discussion pointed to a stark competitive reality, with India underestimating China's rapid ascent in pharmaceutical innovation. GV Prasad noted that China is no longer just a low-cost supplier but a formidable force driven by evolved regulatory pathways and robust state support. This has allowed China to climb the value chain significantly, presenting a direct challenge to India's long-held dominance in certain segments.
Shifting Focus: From Generics to Breakthroughs
While India's market remains heavily skewed towards off-patent generics (97%), segments like biosimilars already demand branding and credibility, signaling the evolving market dynamics. Vinita Gupta of Lupin stressed that the next decade requires a strategic pivot towards India-focused innovation and cost-effective drug development. The panel agreed that leveraging India's vast patient base for clinical trials and focusing on locally relevant R&D are key opportunities. However, success will depend on critical factors: enhanced regulatory support, strategic R&D acquisitions, and, crucially, early demonstrable wins to build confidence among doctors, investors, and companies.
Access and Affordability Remain Core
Y.K. Hamied, a veteran of India's generics revolution, reaffirmed his commitment to access and affordability, recalling his fight against monopolies and efforts to supply affordable HIV/AIDS drugs. He argued that while generics are well-established, the next frontier for Indian innovation lies in gaining acceptance for novel Indian drugs within the medical community. This balance between groundbreaking research and maintaining the 'pharmacy of the world' ethos is the defining challenge for the sector.